ArticleJournal of clinical laboratory analysis2025
Expression Profile of Serum CircFUNDC1 and CircUHRF1 Can Differentiate Between Colorectal Cancer and Inflammatory Bowel Diseases (Ulcerative Colitis and Crohn's Disease).
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Expression Profiles, Biological Functions and Clinical Significance of Circular RNAs in Inflammatory Bowel Disease.Journal of inflammation research · 2026Review
- The effect of combining the enzymolysis of snail digestive enzyme and β-glucanase on the release of flavor inFood chemistry: X · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a worldwide burden. Circular RNAs are promising biomarkers for diagnosing and prognosis of CRC.
objectiveTo investigate the possible association of sera levels of CircFUNDC1 and CircUHRF1 expression with predisposition and clinicopathological findings in CRC, ulcerative colitis (UC), and Crohn's disease (CD) in Egyptian patients.
methodsThe serum levels of CircFUNDC1 and CircUHRF1 were evaluated in 113 Egyptian subjects divided into four groups; CRC (31), UC (26), and CD (25) and compared to healthy controls (31) using quantitative polymerase chain reaction.
resultsThe median values of log2 serum fold change (FC) of CircFUNDC1 in CRC, UC, and CD patients were 9.11, 6.58, and 6.17, respectively. It was upregulated in all case groups. CRC, UC, and CD patients had significantly higher serum CircFUNDC1 levels than controls (p < 0.001). However, there were no significant differences among patient groups (CRC, UC, and CD). The medians of log 2 of serum FC CircUHRF1 in patients with CRC, UC, and CD were -2.00, 3.33, and 3.12, respectively. The CircUHRF1 serum level was lower in the CRC group of patients, with no significant difference between the CRC group and the controls. Serum CircUHRF1 was significantly overexpressed in patients with UC and CD compared to the CRC groups or controls (p < 0.001). By Roc curve analysis, both genes can differentiate CRC patients from inflammatory bowel disease (IBD) patients or healthy controls with p < 0.05.
conclusionSerum CircFUNDC1 is a biomarker for CRC, while CircUHRF1 is a biomarker of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.